Grampet seeks to become the leading oncology medicines producer in Central and Eastern Europe.
“We’re preparing the launch of the first production line of solid oncology medicines in the first half of next year, following an investment of EUR25 million for a capacity of around 10 million therapeutic units a year. By the end of 2019 we will finalize preparations for the production of injectable oncology drugs existent at the factory in Sibiu,” said Grampet Group CEO Gruia Stoica.
The copampny said around 30% of the output of Polisano Pharmaceuticals will go to the domestic market, while the rest will be exported to the 35 markets Polisano already works with, as well as other countries, as the company extends its partnerships.
The medicines factory in Sibiu has 160 employees and an area of 33,000 sqm with state-of-the -art production lines.